CompletedNot applicableNCT06731790

Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections

Studying Rare genetic disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Montpellier
Principal Investigator
Pierre MEYER, MD, RPT
Montpellier University Hospital
Intervention
Blood sampling for inflammatory phenotype analysis(other)
Enrollment
35 enrolled
Eligibility
1-90 years · All sexes
Timeline
2025 – 2025

Study locations (1)

Collaborators

Institut de Recherche en Infectiologie de Montpellier (CNRS) · A*STAR Infectious Diseases Labs

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06731790 on ClinicalTrials.gov

Other trials for Rare genetic disease

Additional recruiting or active studies for the same condition.

See all trials for Rare genetic disease →

← Back to all trials